PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease ReportsCrohn disease
MeSH D003424 - crohn disease
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D015212:Inflammatory bowel diseases
$
Success rate
D003424: 
Crohn disease
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
BioconAdalimumab Hulio  2020-07-06   
Johnson & JohnsonInfliximab Remicade  1998-08-24 $1,552 M Q4/23-Q3/24 
Ustekinumab Stelara  2009-09-25 $10,765 M Q4/23-Q3/24 
SandozAdalimumab Halimatoz  2018-07-26   
Adalimumab Hefiya  2018-07-26   
Adalimumab Hyrimoz  2018-10-30   
Folic acid, Dexpanthenol, Ascorbic acid, Cyanocobalamin, Vitamin a, Alpha-tocopherol, Biotin, Cholecalciferol, Niacinamide, Pyridoxine, Riboflavin, Thiamine, Tocopherol Infuvite  2000-05-18   
Infliximab Zessly  2018-05-18   
Natalizumab Tyruko  2023-08-24   
Methotrexate Methotrexate  2009-03-31   
Boehringer IngelheimAdalimumab Cyltezo  2017-08-25   
OrganonAlendronate, Cholecalciferol Fosamax D  2005-04-07   
AbbVieAdalimumab Humira  2002-12-31 $10,615 M Q4/23-Q3/24 
UCBCertolizumab pegol Cimzia  2008-04-22   
PfizerAdalimumab Abrilada  2019-11-15   
Adalimumab Amsparity  2020-02-13   
Infliximab Inflectra  2013-09-10 $490 M Y2023 
Infliximab Ixifi  2017-12-13   
TakedaVedolizumab Entyvio  2014-05-20   
Rising PharmaceuticalsAzathioprine Azathioprine  1999-12-13   
Methotrexate Methotrexate  2012-03-29   
1
2
3
4
5
6
>
Clinical Trials
Historical Success Rate
Phase 1
86%
61/71
Phase 2
45%
55/122
Phase 3
51%
42/83
Approved: 16Overall Success rate: 20%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Biocon
Johnson & Johnson
1
2
3
4
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use